CardioDx  
心血管疾病基因诊断领域的先锋企业 CardioDx

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to improve treatment decisions. Strategically focused initially on diagnostics for coronary artery disease (CAD), cardiac arrhythmia and heart failure, CardioDx is committed to providing healthcare professionals with critical, actionable information to improve patient care and management through the commercialization of genomic technologies. CardioDx's Corus® CAD test is the first and only commercially available blood-based gene expression test that provides a current-state assessment for non-diabetic patients with symptoms that are suggestive of obstructive CAD. Corus CAD helps clinicians rule out obstructive CAD as the cause of these symptoms.